Gilead Sciences, Inc. · NASDAQ:GILD
Gilead Sciences — 38th Annual J.P. Morgan Healthcare Conference (January 2020)
28 slides from Gilead Sciences's conference presentation, Jan 13, 2020
Slide 1: Gilead's Next Chapter
Gilead’s Next Chapter Daniel O’Day Chairman and Chief Executive Officer January 13, 2020 Confidential – Internal Use Only
Slide 2: Forward-Looking Statements
Forward-Looking Statements Statements included in this presentation that are not historical in nature could be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain
Slide 3: Three Pillars of Gilead's Next Chapter
Three Pillars of Gilead’s Next Chapter Durable Core Existing Pipeline Strategy to Drive Business Opportunities Additional Growth + + 3 Confidential – Internal Use Only
Slide 4: Key Decisions Have Laid the Foundation for Change
Key Decisions Have Laid the Foundation for Change Made Kite Expanded Established Completed New Defined New Separate Operating Galapagos External Innovation Leadership Corporate Company Partnership Group Team Strategy Mar Jul Sep Oct Dec 2020 2019 4 Confidential – Internal Use Only
Slide 5: Diverse, Highly Experienced Leadership Team
Diverse, Highly Experienced Leadership Team Daniel O’Day Andrew Dickinson Brett A. Pletcher Christi Shaw Johanna Mercier Executive Chairman and Chief Financial Officer Executive Vice President, Chief Executive Officer, Kite Chief Commercial Officer Chief Executive Officer Corporate Affairs and Gener
Slide 6: Building from Durable Core Business
Building from Durable Core Business Durable Core Existing Pipeline Strategy to Drive Business Opportunities Additional Growth + + 6 Confidential – Internal Use Only
Slide 7: Robust Growth of HIV Business Despite Competitor Launches
Robust Growth of HIV Business Despite Competitor Launches • Antiviral world-leader HCV ‒ 15 launches in 10 years1 Other HIV • Robust HIV growth ‒ 14% CAGR since 20112 ‒ 13% growth Q3’18 – Q3’19 2011 2019 Prepared for • Treatment - 90-95% Gilead patients expected on F/TAF-based regimens by Q4’203 Tru
Slide 8: HIV Franchise is Robust and Sustainable
HIV Franchise is Robust and Sustainable Highly effective single tablet Statistically significant safety regimen for treatment improvements in prevention5 • Zero cases of treatment-emergent resistance • ~20% at-risk individuals on PrEP today6 and rapid start recommended1,2 • ~25% PrEP scripts are for
Slide 9: Reinforcing Commitment to HIV Leadership With Innovative Long-Acting Programs
Reinforcing Commitment to HIV Leadership With Innovative Long-Acting Programs Capsid Inhibitor as the Foundation • Weekly oral potential Current Clinical Programs HTE2 P2/3 • Monthly 6 month SQ with self-admin potential Virologically Suppressed P2 Treatment PrEP PC + • Breakthrough Designation1 Pr
Slide 10: Additional Opportunities to Grow Antiviral Business
Additional Opportunities to Grow Antiviral Business Sustain HCV Accelerate Drive China Revenues HBV Growth Key market leadership Achieve $1bn+ franchise by 2022 8 products approved since 2017 ~60% U.S. market share today1 through U.S. and China Vemlidy 4 listed on NRDL for Jan 2020 growth reimbursem
Slide 11: Executing on Existing Pipeline Opportunities
Executing on Existing Pipeline Opportunities Durable Core Existing Pipeline Strategy to Drive Business Opportunities Additional Growth + + 11 Confidential – Internal Use Only
Slide 12: Overview of Clinical Pipeline Today
Overview of Clinical Pipeline Today Phase 1 Phase 2 Phase 3 NDA/BLA/MAA Clinical Stage Viral Diseases 41 Programs NDA/BLA/MAA, P3 and Inflammatory 14 Registrational P2 trials Diseases NMEs via in-licensing, Fibrotic Diseases 13 options, and product acquisitions 4 Breakthrough Therapy Oncology Design
Slide 13: Filgotinib Marks Expansion into Inflammation with Potential for 5 Launches in Next 4 Years
Filgotinib Marks Expansion into Inflammation with Potential for 5 Launches in Next 4 Years Filgotinib RA P3 Selective JAK-1 inhibitor with potential best-in-class profile UC P3 Strong efficacy for remission and demonstrated safety CD P3 at both doses; favorable benefit/risk profile at high dose PsA
Slide 14: Building a Broad Inflammation and Fibrosis Portfolio with Galapagos Beyond Filgotinib
Building a Broad Inflammation and Fibrosis Portfolio with Galapagos Beyond Filgotinib GLPG-16902 – IPF P3 GLPG-1972 – OA P2 GLPG-12053 – IPF P2 8 clinical GLPG-16902 – Systemic Sclerosis P2 programs1 GLPG-0555 – Inflammation P1 GLPG-39704 – Inflammation P1 GLPG-33124 – Inflammation P1 GLPG-3667 – In
Slide 15: Oncology Strategy Focused on Immuno-Oncology
Oncology Strategy Focused on Immuno-Oncology Building transformative therapies across complementary Immuno-Oncology platforms Cell Therapy Non-Cell Therapy Pioneering platform Transformative therapy Apply small molecule and biologics to advance new therapies and with potential for earlier lines deve
Slide 16: Oncology Pipeline Consists of 15 Clinical Programs and Growing
Oncology Pipeline Consists of 15 Clinical Programs and Growing Building transformative therapies across complementary Immuno-Oncology platforms Cell Therapy Non-Cell Therapy KTE-X19 CD-19 r/r MCL BLA Oral PD-L1 inhibitor (GS-4224) Solid tumors P1 Axi-cel CD-19 2L DLBCL P3 Anti-CD73/TGFβ TRAP (GS-142
Slide 17: Anticipated Milestones Through 2021
Anticipated Milestones Through 2021 Axi-cel Axi-cel P3 2L DLBCL data Expected iNHL approval Filgotinib Axi-cel Expected RA approvals in U.S., Europe, Japan Expected 2L DLBCL submission Filgotinib Axi-cel P3 enrollment completion for CD P2 1L DLBCL data Axi-cel Filgotinib Capsid inhibitor P2 iNHL dat
Slide 18: Strategy to Drive Additional Growth
Strategy to Drive Additional Growth Durable Core Existing Pipeline Strategy to Drive Business Opportunities Additional Growth + + 18 Confidential – Internal Use Only
Slide 19: New Corporate Strategy to Drive Future Growth
New Corporate Strategy to Drive Future Growth Long-Term Ambitions Bring 10+ Transformative Be the Biotech Employer and Deliver Shareholder Value in a Therapies to Patients by 2030 Partner of Choice Sustainable, Responsible Manner Strategic Priorities Strengthen Portfolio Expand Internal and Increase
Slide 20: Focused on Growing from Core Areas of Strength
Focused on Growing from Core Areas of Strength Core Strengths Disease Areas Viral Inflammatory Diseases Diseases Immuno- Antivirals modulation Deep Expertise Emerging Expertise Fibrotic Oncology Diseases 20 Confidential – Internal Use Only
Slide 21: We Will Continue to Pursue Tailored Transactions That Drive Strategic Value
We Will Continue to Pursue Tailored Transactions That Drive Strategic Value Guiding Principles for Future Deals 32 • Focus on high quality science that build upon core areas of strength • Prioritize clinical and commercial opportunities • Pursue and execute: Strategic Partnerships & Investment Trans
Slide 22: Three Pillars of Gilead's Next Chapter
Three Pillars of Gilead’s Next Chapter Durable Core Existing Pipeline Strategy to Drive Business Opportunities Additional Growth + + Well positioned to maximize near-term opportunities and achieve long-term success 22 Confidential – Internal Use Only
Slide 23: Gilead's Next Chapter
Gilead’s Next Chapter Daniel O’Day Chairman and Chief Executive Officer January 13, 2020 Confidential – Internal Use Only
Slide 24: Appendix
Appendix Confidential – Internal Use Only
Slide 25: Viral Disease Pipeline
Viral Disease Pipeline Pre-Clinical Phase 1 Phase 2 Phase 3 Biktarvy HIV treatment pediatric1 Capsid inhibitor (GS-6207) HIV HTE Registrational for HTE2 Capsid inhibitor (GS-6207) HIV virologically suppressed Vesatolimod (GS-9620, TLR-7 agonist) HIV cure HIV Elipovimab (GS-9722, bNAb) HIV cure Capsi
Slide 26: Inflammatory Disease Pipeline
Inflammatory Disease Pipeline Pre-Clinical Phase 1 Phase 2 Phase 3 NDA/BLA/MAA Filgotinib (GS-6034, JAK-1 inhibitor) Rheumatoid arthritis NDA/MAA Filgotinib (GS-6034, JAK-1 inhibitor) Ulcerative colitis Filgotinib (GS-6034, JAK-1 inhibitor) Crohn’s disease Filgotinib (GS-6034, JAK-1 inhibitor) Psori
Slide 27: Fibrotic Disease Pipeline
Fibrotic Disease Pipeline Pre-Clinical Phase 1 Phase 2 Phase 3 Cilofexor (GS-9674, FXR agonist) PSC GLPG-1690* Idiopathic pulmonary fibrosis Fibrotic Disease Cilofexor (FXR agonist), Firsocostat (ACC NASH inh.), Selonsertib (ASK1 inh.) combinations Selonsertib (GS-4997, ASK1 inhibitor) DKD GLPG-1690
Slide 28: Oncology Pipeline
Oncology Pipeline Pre-Clinical Phase 1 Phase 2 Phase 3 NDA/BLA/MAA KTE-X19 MCL BLA Axi-cel 2L DLBCL Axi-cel Indolent NHL Pivotal Axi-cel 1L DLBCL Axi-cel DLBCL (+rituximab or lenalidomide) Pivotal Cell Therapy KTE-X19 Adult ALL Pivotal KTE-X19 Pediatric ALL Pivotal KTE-X19 CLL Axi-cel DLBCL (+4-1BB
Gilead Sciences — 38th Annual J.P. Morgan Healthcare Conference (January 2020) on 6ix